Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00363714 | A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) | PHASE1 | COMPLETED | 26 | — | — | Nov 1, 2004 | Apr 1, 2007 | Aug 18, 2008 | 2 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Single intravitreal injection |
| 2 | EXPERIMENTAL | Single intravitreal injection |
| 3 | EXPERIMENTAL | Single intravitreal injection |
| 4 | EXPERIMENTAL | Single intravitreal injection |
| 5 | EXPERIMENTAL | Single intravitreal injection |
| 6 | EXPERIMENTAL | Single intravitreal injection |
| Name | Type | Description |
|---|---|---|
| AGN211745 | DRUG | 100microgram single intravitreal injection |
Inclusion Criteria: * Active AMD with Subfoveal CNV (classic and/or occult CNV) * CNV lesion thickness \>/= 250um by OCT assessment * Visual acuity in study eye of \</= 20/100 but not worse than 20/800 * Not eligible for or refused standard treatment Exclusion Criteria: * Females of childbearing ...